U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H18ClN3O3S
Molecular Weight 355.84
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIARAMIDE

SMILES

OCCN1CCN(CC1)C(=O)CN2C(=O)SC3=C2C=C(Cl)C=C3

InChI

InChIKey=HTJXMOGUGMSZOG-UHFFFAOYSA-N
InChI=1S/C15H18ClN3O3S/c16-11-1-2-13-12(9-11)19(15(22)23-13)10-14(21)18-5-3-17(4-6-18)7-8-20/h1-2,9,20H,3-8,10H2

HIDE SMILES / InChI
Tiaramide is an anti-inflammatory and analgesic drug, which was developed by Fujisawa Pharmaceutical (now Astellas pharma) and used in Japan under the name Solantol for the treatment of different pain and inflammatory disorders. Later on, Astellas recalled the product by reasons other than safety. The mechanism of tiaramide action is unknown.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SOLANTAL

Approved Use

Pain management after surgery, tooth extraction and trauma, pain relief in arthritis, low back pain, cervical shoulder arm syndrome, pelvic inflammation, birth canal injuries, breast engorgement, herpes zoster, polymorphic exudative erythema, cystitis, epididymitis, uveitis, pericoronitis, acute upper respiratory tract inflammation.

Launch Date

1974
Palliative
SOLANTOL

Approved Use

Pain management after surgery, tooth extraction and trauma, pain relief in arthritis, low back pain, cervical shoulder arm syndrome, pelvic inflammation, birth canal injuries, breast engorgement, herpes zoster, polymorphic exudative erythema, cystitis, epididymitis, uveitis, pericoronitis, acute upper respiratory tract inflammation.

Launch Date

1974
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.79 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIARAMIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.7 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIARAMIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.36 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIARAMIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.59 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIARAMIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.34 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIARAMIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
51%
TIARAMIDE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
500 mg 2 times / day multiple, oral
Highest studied dose
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Loss of consciousness...
Other AEs: Seizures...
AEs leading to
discontinuation/dose reduction:
Loss of consciousness
Other AEs:
Seizures
Sources:
200 mg 4 times / day multiple, oral
Recommended
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Convulsion...
Other AEs: Loss of consciousness...
AEs leading to
discontinuation/dose reduction:
Convulsion
Other AEs:
Loss of consciousness
Sources:
AEs

AEs

AESignificanceDosePopulation
Seizures
500 mg 2 times / day multiple, oral
Highest studied dose
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Loss of consciousness Disc. AE
500 mg 2 times / day multiple, oral
Highest studied dose
Dose: 500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 500 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Loss of consciousness
200 mg 4 times / day multiple, oral
Recommended
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Convulsion Disc. AE
200 mg 4 times / day multiple, oral
Recommended
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells.
2008-10-31
Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives.
2007-07
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
2007-03
Strategy for structure elucidation of drug metabolites derived from protonated molecules and (MS)n fragmentation of zotepine, tiaramide and their metabolites.
2002
Patents

Sample Use Guides

The recommended dose is 1 tablet (100 mg) once daily. In patients with acute upper respiratory tract inflammation the dose may be increased up to 3 tablets.
Route of Administration: Oral
In Vitro Use Guide
Tiaramide in 10(-4) and 10(-5)M inhibited effectively the platelet aggregation caused by ADP.
Name Type Language
RHC 2592A
Preferred Name English
TIARAMIDE
INN   MI   WHO-DD  
INN  
Official Name English
1-PIPERAZINEETHANOL, 4-((5-CHLORO-2-OXO-3(2H)-BENZOTHIAZOLYL)ACETYL)
Common Name English
2(3H)-BENZOTHIAZOLONE, 5-CHLORO-3-(2-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)-2-OXOETHYL)-
Systematic Name English
TIARAMIDE [MI]
Common Name English
Tiaramide [WHO-DD]
Common Name English
RHC-2592A
Code English
tiaramide [INN]
Common Name English
TIALAMIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C319
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
Code System Code Type Description
MESH
C003468
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
FDA UNII
BB17WGM686
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
ChEMBL
CHEMBL274239
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
INN
3070
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
MERCK INDEX
m10849
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY Merck Index
PUBCHEM
5469
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
EPA CompTox
DTXSID0023666
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
ECHA (EC/EINECS)
251-083-7
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
NCI_THESAURUS
C152603
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
DRUG CENTRAL
2653
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
EVMPD
SUB11013MIG
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
SMS_ID
100000082161
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY
CAS
32527-55-2
Created by admin on Mon Mar 31 18:57:47 GMT 2025 , Edited by admin on Mon Mar 31 18:57:47 GMT 2025
PRIMARY